We are pleased to present updated results from our ongoing BRAVO study and are committed to collecting longer-term data on the use of OviTex Reinforced BioScaffolds to support improved patient care and address the needs of surgeons and healthcare systems," said Maarten Persenaire, M.D., chief medical officer of TELA Bio.
Publication of Case Series Evaluating OviTex® Reinforced BioScaffolds in Hiatal and Inguinal Hernia Repair
9/11/18: "As we continue to work to expand patient access and provide OviTex RBSs to hospital networks across the U.S., we also remain focused on collecting important feedback and real-world insights from surgeons who now have extensive experience with nearly 3,000 hernia repair procedures completed to date," said Maarten Persenaire, chief medical officer of TELA Bio.
Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction Presented at Americas Hernia Society International Hernia Congress 2018
3/12/18: Data presented at Americas Hernia Society International Hernia Congress 2018 show low recurrence and complication rates.